Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stake Raised by Fairmount Funds Management LLC
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stake Raised by Fairmount Funds Management LLC
Fairmount Funds Management LLC lifted its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 21.1% during the 1st quarter, HoldingsChannel reports. The fund owned 469,264 shares of the biotechnology company's stock after purchasing an additional 81,864 shares during the period. Enanta Pharmaceuticals accounts for 7.9% of Fairmount Funds Management LLC's portfolio, making the stock its 5th biggest position. Fairmount Funds Management LLC's holdings in Enanta Pharmaceuticals were worth $33,402,000 as of its most recent filing with the Securities & Exchange Commission.
據HoldingsChannel報道,Fairmount Funds Management LLC在第一季度將其在Enanta製藥公司(納斯達克代碼:Enta-Get Rating)的股票頭寸提高了21.1%。該基金持有這家生物技術公司469,264股,在此期間又購買了81,864股。Enanta PharmPharmticals在Fairmount Funds Management LLC的投資組合中佔7.9%,使該股成為其第五大頭寸。截至最近提交給美國證券交易委員會的文件,Fairmount Funds Management LLC在Enanta PharmPharmticals持有的股份價值33,402,000美元。
Several other hedge funds have also modified their holdings of ENTA. Signaturefd LLC increased its holdings in shares of Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company's stock worth $28,000 after buying an additional 182 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Enanta Pharmaceuticals by 343.8% during the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 660 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $85,000. KBC Group NV acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $113,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $114,000. 97.09% of the stock is owned by hedge funds and other institutional investors.
其他幾家對衝基金也調整了對Enta的持股。Signaturefd LLC在第一季度增持了Enanta製藥公司的股票86.7%。Signaturefd LLC現在持有這家生物技術公司392股股票,價值2.8萬美元,在上個季度又購買了182股。CapTrust Financial Advisors在第一季度將其在Enanta製藥公司的股份增加了343.8%。CapTrust Financial Advisors在此期間額外購買了660股,現在擁有852股這家生物技術公司的股票,價值6.1萬美元。C M Bidwell&Associates Ltd.在第四季度收購了Enanta製藥公司價值約85,000美元的新股票頭寸。KBC Group NV在第一季度收購了價值約11.3萬美元的Enanta製藥公司股票的新頭寸。最後,Point72 Hong Kong Ltd在第四季度收購了價值約11.4萬美元的Enanta PharmPharmticals股票。97.09%的股票由對衝基金和其他機構投資者持有。
Enanta Pharmaceuticals Price Performance
Enanta製藥價格表現
Shares of NASDAQ ENTA traded down $0.98 on Monday, hitting $63.06. The company's stock had a trading volume of 5,707 shares, compared to its average volume of 239,682. Enanta Pharmaceuticals, Inc. has a 12-month low of $37.59 and a 12-month high of $102.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -10.73 and a beta of 0.55. The stock has a 50 day moving average of $59.75 and a 200-day moving average of $58.66.
週一,納斯達克恩塔的股價下跌0.98美元,至63.06美元。該公司股票的成交量為5,707股,而其平均成交量為239,682股。Enanta PharmPharmticals,Inc.的12個月低點為37.59美元,12個月高位為102.00美元。該公司市值13.1億美元,市盈率為-10.73倍,貝塔係數為0.55。該股的50日移動均線切入位在59.75美元,200日移動均線切入位在58.66美元。
Analyst Ratings Changes
分析師評級發生變化
A number of brokerages have recently issued reports on ENTA. SVB Leerink boosted their price target on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a "market perform" rating in a research note on Monday, August 1st. Royal Bank of Canada decreased their price objective on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th. Evercore ISI raised shares of Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. Oppenheimer boosted their price objective on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a "market perform" rating in a report on Wednesday, August 10th. Finally, Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an "outperform" rating on the stock in a report on Thursday, May 19th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $78.63.
多家券商近期發佈了有關Enta的報告。SVB Leerink在8月1日週一的一份研究報告中將Enanta PharmPharmticals的股票目標價從44.00美元上調至50.00美元,並給出了該股的“市場表現”評級。加拿大皇家銀行在8月9日(星期二)的一份報告中將埃南塔製藥的股票目標價從67.00美元下調至66.00美元,並對該股設定了“行業表現”評級。Evercore ISI在7月6日(星期三)的一份報告中將Enanta PharmPharmticals的股票評級從“在線”上調至“表現優於大盤”,併為該股設定了62.00美元的目標價。奧本海默在8月10日(星期三)的一份報告中將Enanta製藥公司的股票目標價從53.00美元上調至59.00美元,並給予該股“市場表現”評級。最後,羅伯特·W·貝爾德在5月19日星期四的一份報告中將埃南塔製藥公司的股票目標價從130.00美元下調至90美元,並對該股設定了“跑贏大盤”的評級。四名分析師對該股的評級為持有,五名分析師對該公司的評級為買入。根據MarketBeat的數據,Enanta PharmPharmticals目前的共識評級為“中等買入”,平均目標價為78.63美元。
Enanta Pharmaceuticals Profile
Enanta製藥公司簡介
(Get Rating)
(獲取評級)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta製藥公司是一家生物技術公司,發現和開發用於治療病毒感染和肝病的小分子藥物。其研發的疾病靶標包括呼吸道合胞病毒、SARS-CoV-2、人類偏肺病毒和乙肝病毒。該公司與雅培簽訂了一項合作開發和許可協議,以識別、開發和商業化丙型肝炎病毒NS3和NS3/4A蛋白酶抑制劑化合物,包括用於治療慢性丙型肝炎病毒的paritaprevir和glecapvir。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- 免費獲取StockNews.com關於Enanta製藥公司(Enta)的研究報告
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
- 3只生物科技股勢頭強勁
- 電子藝界能扭轉電子遊戲市場的低迷嗎?
- 美元將軍是美國小池塘裏的大魚。
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating).
想看看其他對衝基金持有Enta的股份嗎?訪問HoldingsChannel.com以獲取Enanta製藥公司(納斯達克:Enta-Get Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Enanta製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Enanta製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。